Precision BioSciences, Inc. - DTIL
About Gravity Analytica
Recent News
- 05.15.2025 - Precision BioSciences Muscle Programs Update
- 05.15.2025 - Precision BioSciences Muscle Programs Update
- 05.15.2025 - Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
- 05.15.2025 - Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
- 05.15.2025 - ARCUS-Mediated Excision of Exons 45-55 of the Human Dystrophin Gene using PBGENE-DMD Leads to Durable Muscle Function Improvements In Vivo as a Result of Functional Dystrophin Protein Restoration for the Treatment of Duchenne Muscular Dystrophy
- 05.15.2025 - Systemic Delivery of a Mitochondria-Targeting ARCUS Gene Editing Nuclease by AAV Eliminates Mutant Mitochondrial DNA, Demonstrating Therapeutically Meaningful Heteroplasmy Shifts In Vivo
- 05.14.2025 - Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
- 05.14.2025 - Precision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
- 05.14.2025 - Excision of the C9orf72 Hexanucleotide Repeat Expansion Using a Dual-ARCUS Gene Editing Approach Delivered by a Single AAV Reduces Neurotoxic RNA Foci and Dipeptides in an In Vivo Model of ALS
- 05.08.2025 - Precision BioSciences to Report First Quarter 2025 Results on May 15, 2025